Prescription ·Strong evidence ·Reviewed May 2026
Rosuvastatin is a high-intensity statin and one of the most potent agents for lowering LDL cholesterol. The JUPITER trial demonstrated its benefit in primary prevention among patients with elevated high-sensitivity C-reactive protein even without hyperlipidemia.
The bottom line
Evidence rating strong. Most-documented uses: lowers ldl cholesterol by 45–63%, reduces cardiovascular events in primary and secondary prevention, raises hdl cholesterol modestly. 12 sources indexed (2021–2025), with 6 interaction records on file.
Core mechanism
Selectively and competitively inhibits HMG-CoA reductase in the liver. Rosuvastatin is hydrophilic with high hepatic selectivity, resulting in potent LDL-C reduction with relatively lower systemic muscle exposure. Upregulates hepatic LDL receptors, increases LDL clearance, and reduces VLDL synthesis.2,3
Can be taken with or without food at any time of day; hydrophilic statin not dependent on CYP3A4 metabolism3
Nutrients this medication can lower over time, and what to replace.
HMG-CoA reductase inhibition reduces mevalonate pathway flux, lowering endogenous CoQ10 synthesis alongside cholesterol synthesis.
Rosuvastatin, like all statins, inhibits the mevalonate pathway and reduces endogenous CoQ10 production. This depletion may contribute to statin-associated muscle symptoms. CoQ10 supplementation can help restore levels and may alleviate myalgia in some patients.
Recommendation: Consider CoQ10 supplementation (100-200mg/day ubiquinol) if experiencing statin-related muscle symptoms. CoQ10 does not interfere with rosuvastatin's cholesterol-lowering effect.
St. John's Wort induces CYP3A4 and P-glycoprotein, which can reduce rosuvastatin levels. While rosuvastatin is less dependent on CYP3A4 than other statins, P-glycoprotein induction can still significantly reduce its bioavailability, potentially compromising cholesterol management.
Recommendation: Avoid combining St. John's Wort with rosuvastatin. P-glycoprotein induction may reduce rosuvastatin absorption even though it is not primarily CYP3A4-metabolized.
High-dose niacin combined with rosuvastatin increases myopathy risk. Clinical trials have shown that adding niacin to statin therapy does not provide additional cardiovascular benefit but does increase the incidence of muscle-related adverse effects.
Recommendation: Avoid high-dose niacin (>500mg/day) with rosuvastatin without medical supervision. Low-dose niacin for general health purposes is generally safe. Report any muscle pain or weakness promptly.
Statins inhibit HMG-CoA reductase, which is also upstream of CoQ10 synthesis in the mevalonate pathway. Rosuvastatin can reduce plasma CoQ10 by 40%. CoQ10 supplementation may alleviate statin-associated myalgia.
Recommendation: Consider CoQ10 100-200mg/day if experiencing muscle symptoms on rosuvastatin. CoQ10 does not interfere with rosuvastatin's cholesterol-lowering effect.
Repeated green tea extract significantly reduced systemic rosuvastatin exposure in healthy volunteers. This could reduce or unpredictably alter rosuvastatin's lipid-lowering effect, especially with concentrated high-EGCG products. The effect may vary by transporter genetics.
Recommendation: Avoid starting high-dose green tea extract without checking whether your LDL response remains controlled on rosuvastatin. If you use it, keep the dose consistent and recheck lipid labs after starting, stopping, or changing the extract.
Fish oil omega-3 fatty acids can be used with rosuvastatin for residual hypertriglyceridemia. Human pharmacokinetic studies found no clinically important interaction between omega-3 fatty acid products and rosuvastatin. The expected benefit is triglyceride lowering, not extra LDL lowering.
Recommendation: Consider fish oil with rosuvastatin if triglycerides remain elevated and you can use a reliable, consistent product. Recheck fasting lipids after starting because LDL cholesterol can respond differently depending on the omega-3 formulation.
Numbered references. Citations throughout the page link here.
Statin use, particularly with lipophilic statins, was associated with a significant reduction in dementia risk in this updated systematic review and meta-analysis
González-Iglesias E, Novalbos J, Abad-Santos F. The pharmacogenetics of rosuvastatin and implications for treatment: a systematic review. Pharmacogenomics. 2025
Moderate-intensity rosuvastatin/ezetimibe combination therapy showed comparable or superior LDL-C reduction to quadruple-dose rosuvastatin monotherapy with potentially fewer side effects
Liu L, Deng Y, Li L et al.. Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis. PloS one. 2024
Singh H, Kaur S, Kaushal P et al.. Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis. Expert review of clinical pharmacology. 2024
Kanukula R, Salam A, Rodgers A et al.. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical pharmacokinetics. 2021
Moon JS, Park IR, Kim SS et al.. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & metabolism journal. 2023
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack